### CHEM-A Internal Request:
**Suggestion made to review the evidence for carboplatin/infusional 5-U for non-nasopharyngeal cancers.**

Based upon discussion and the noted reference, the panel consensus was to change the following under Squamous Cell Cancers: Primary systemic therapy + concurrent RT: For non-nasopharyngeal cancers, “Carboplatin/infusional 5-FU” from category 2A to category 1.

**References**


**Vote**

YES 21  NO 0  ABSTAIN 0

### CHEM-A Internal Request:
**Review the induction/sequential chemotherapy regimens for non-nasopharyngeal cancers**

Based upon discussion and the noted reference, the panel consensus was to add Paclitaxel/cisplatin/infusional 5-FU” as an Induction/Sequential chemotherapy regimen For non-nasopharyngeal cancers

**References**


**Vote**

YES 21  NO 0  ABSTAIN 0

### CHEM-A Internal Request:
**Suggest adding a section on Induction/Sequential chemotherapy for nasopharynx cancers.**

Based upon discussion the panel consensus was to add the following section denoting Induction/Sequential chemotherapy for nasopharynx cancers:
- Docetaxel/cisplatin/5-FU
- Cisplatin/5-FU
- Cisplatin/epirubicin/paclitaxel
- Following induction, agents to be used with concurrent chemoradiation typically include weekly cisplatin or carboplatin


**Vote**

YES 21  NO 0  ABSTAIN 0